94 related articles for article (PubMed ID: 16857826)
1. Novel combinations based on epidermal growth factor receptor inhibition.
Adjei AA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4446s-4450s. PubMed ID: 16857826
[TBL] [Abstract][Full Text] [Related]
2. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
5. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
6. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
7. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
8. Novel agents on the horizon for cancer therapy.
Ma WW; Adjei AA
CA Cancer J Clin; 2009; 59(2):111-37. PubMed ID: 19278961
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of epidermal growth factor receptor-dependent signaling by Porphyromonas gingivalis lipopolysaccharide in life-expanded human gingival fibroblasts.
Quinchia-Rios BH; Guerrero M; Abozeid S; Bainbridge B; Darveau R; Compton T; Bertics PJ
J Periodontal Res; 2008 Jun; 43(3):290-304. PubMed ID: 18221293
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.
Renhowe PA
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):214-24. PubMed ID: 11926128
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
14. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
17. Exploring multi-targeting strategies for the treatment of gliomas.
Omuro AM
Curr Opin Investig Drugs; 2008 Dec; 9(12):1287-95. PubMed ID: 19037835
[TBL] [Abstract][Full Text] [Related]
18. The epidermal growth factor receptor pathway: a model for targeted therapy.
Scaltriti M; Baselga J
Clin Cancer Res; 2006 Sep; 12(18):5268-72. PubMed ID: 17000658
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Hartmann JT
Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
[TBL] [Abstract][Full Text] [Related]
20. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]